Targacept to Present at BIO 2002 International Investor Forum
Winston-Salem, NC
June 06, 2002
Targacept, Inc., a privately held pharmaceutical research and development company, will present an update of the company's progress at the BIO 2002 International Biotechnology Investor Forum in Toronto.
| WHO: | J. Donald deBethizy, Ph.D. |
| President and Chief Executive Officer | |
| Targacept, Inc. | |
| WHEN: | June 10, 2002 at 4:00 p.m. |
| WHERE: | BIO 2002 International Biotechnology Convention & Exhibition |
| Metro Toronto Convention Centre | |
| Room B | |
| Toronto, Ontario, Canada |
Dr. deBethizy's presentation will be available live via Thomson Financial webcasting and will also be made available up to 90 days after the event. Registration for the webcast can be made through the following link:
http://events01.activate.net/thomson/bio/2946
A link to the main index page with all of the presenting companies can be found at: http://events01.activate.net/thomson/bio/registration/default.asp
Targacept is a world leader in the discovery and development of neuronal nicotinic receptor-based therapies for neurodegenerative, neuropsychiatric and gastrointestinal diseases. The company has products in research and development for treating Alzheimer's disease, Parkinson's disease, Lewy Body dementia, ulcerative colitis, depression, pain, attention deficit disorder and Tourette's syndrome.
Targacept was established in 1997 as a wholly owned subsidiary of R.J. Reynolds Tobacco Company. It was spun out in August 2000, in one of the largest ($30.4 million) first-round venture capital financings in U.S. biotech history and the largest in North Carolina biotech history. The company has strategic alliances with Aventis Pharmaceuticals of Strasbourg, France and Dr. Falk Pharma of Freiburg, Germany. Targacept was named Pharmaceutical Company of the Year by NCEITA in 2001.
Back to Newsroom